eGenesis raises $191 million Series D to advance EGEN-2784 kidney transplant program

eGenesis/EGEN-2784

eGenesis completed a Series D funding round raising $191 million led by Lux Capital with participation from Khosla Ventures and ARCH Venture Partners. The capital will support advancement of EGEN-2784 to a first-in-human clinical study, scale manufacturing, and pursue additional pipeline programs in cell therapy.

• Series D brings total company funding to $456 million.
• Funds directed to EGEN-2784 clinical trial advancement and manufacturing scale-up.
• Investors include repeat backers and new institutional capital.